TABLE 3.
Baseline characteristics before the initiation of alectinib (n = 61)
| Number (percentage) | |
|---|---|
| Reasons for the discontinuation of crizotinib | |
| Disease progression | 52 (85.2%) |
| Severe adverse events | 7 (11.5%) |
| Patient preferences | 2 (3.3%) |
| Median age | 49 (range 28, 81) |
| <65 | 53 (86.9%) |
| ≥65 | 8 (13.1%) |
| ECOG | |
| 0–1 | 40 (65.6%) |
| ≥2 | 21 (34.4%) |
| CNS metastases | |
| Yes | 38 (62.3%) |
| No | 23 (37.7%) |
| Distant organs involved | |
| 0 | 3 (4.9%) |
| 1–2 | 38 (62.3%) |
| ≥3 | 20 (32.8%) |
| Target lesions | |
| Yes | 46 (75.4%) |
| No | 15 (24.6%) |